You are here

Article Text

Article menu
Download PDFPDF
Case report
Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib
  1. Kristen Zeitler1,
  2. Ripal Jariwala2,
  3. Sally Alrabaa3 and
  4. Chakrapol Sriaroon4
  1. 1Department of Pharmacy, Tampa General Hospital, Tampa, Florida, USA
  2. 2Department of Pharmacy, University of California San Francisco, San Francisco, California, USA
  3. 3Division of Infectious Diseases and International Medicine, Department of Internal Medicine, University of South Florida, Tampa, Florida, USA
  4. 4Pulmonary/Critical Care, University of South Florida, Tampa, Florida, USA
  1. Correspondence to Dr Chakrapol Sriaroon; csriaro{at}health.usf.edu

Abstract

Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions and its mechanism of action involves suppression of the immune system. While beneficial in treatment of polycythemia vera, myelofibrosis and other indications, it can also increase a patient’s susceptibility to various infections, including bacterial, viral and fungal. We present a case of a patient being treated with RUX who presented with a disseminated fungal infection. This case emphasises the need for vigilance of endemic fungal infections in individuals who are on RUX therapy.

  • infections
  • malignant disease and immunosuppression

https://doi.org/10.1136/bcr-2021-243694

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors KZ, RJ, SA and CS: planning of manuscript, conception and design for writing, acquisition of data, interpretation of data, writing and revision of manuscript and editing/approval of final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.